Congratulations to Mr. WANG Zilong on his election as a new DCVMN Executive Committee Member

The 23rd Annual General Meeting of the Developing Countries Vaccine Manufactures Network (DCVMN) was held in Pune, India, from 20-22 October 2022. After online and offline voting by DCVMN members, Mr. WANG Zilong, one of the key members of the Preparatory Organizing Committee of the Council for the Promotion of International Vaccine Cooperation (CPIVC), was successfully elected for the term of 2023-2025, and is the only Chinese vaccine company representative in the current Executive Committee.

Mr. WANG is currently the Director of Business Development of Yunnan Walvax Biotechnology and General Manager of its subsidiary Shanghai Wotai Biotechnology, and was previously part of the multinational biotechnology company Amgen. Since joining Walvax Biotech in 2012, he has been leading and deeply involved in the company’s overall internationalization efforts. With nearly three decades of experience and knowledge in biopharmaceutical research, business development and general management, Mr. WANG has led Walvax Biotechnology to launch and rapidly grow the company’s international business. In recent years, Walvax Biotechnology has gained increasing international attention and recognition, with its vaccine products being marketed and registered in dozens of countries.

DCMVN is a voluntary public health-driven alliance of vaccine manufacturers from developing countries, firmly engaged in research, development, manufacturing and supply of high-quality vaccines that are accessible to protect people against known and emerging infectious diseases globally. The alliance has established good relationships with international organisations such as the World Health Organization (WHO), Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), PATH, and the Bill & Melinda Gates Foundation. The main objective is to provide a consistent and sustainable supply of quality vaccines at an affordable price to developing countries. Currently they have a total of 43 member companies from 15 countries and regions.

From 2023, Mr. WANG Zilong will be a new Executive Committee member of DCVMN, working with representatives of leading vaccine companies from other developing countries to strengthen international exchanges and cooperation in the vaccine community, promote innovative vaccine technologies and enhance vaccine production in developing countries. At the same time, as a key member of the Preparatory Organizing Committee of the Council for the Promotion of International Vaccine Cooperation (CPIVC), Mr. WANG Zilong is actively involved in the preparatory work and will continue to provide more opportunities for international exchanges, cooperation and going abroad for Chinese vaccine companies through the platform of the Council, linking resources of the biopharmaceutical industry and promoting local, regional and even global cooperation throughout the whole vaccine value chain.